EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade

Lucy S Wang iD, Rebecca A Hubbard, Ronac Mamtani

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5798 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Lucy S Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Abramson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Although recent trials involving first‐line immune checkpoint inhibitors have expanded treatment options for patients with advanced urothelial carcinoma (aUC) who are ineligible for standard cisplatin‐based chemotherapy, there exists limited evidence for whether trial efficacy translates into real‐world effectiveness for patients seen in routine care. This retrospective cohort study compares differences in overall survival (OS) between KEYNOTE‐052 trial participants and routine‐care patients receiving first‐line pembrolizumab monotherapy.

Methods

A routine‐care patient cohort was constructed from the Flatiron Health database using trial eligibility criteria and was weighted to balance EHR and trial patient characteristics using matching‐adjusted indirect comparisons.

Results

The routine‐care cohort was older, more likely to be female, and more often cisplatin‐ineligible due to renal dysfunction. ECOG performance status was comparable between the cohorts. Median OS was 9 months (95% CI 7–16) in the weighted routine‐care cohort and 11.3 months (9.7–13.1) in the trial cohort. No significant differences between the Kaplan–Meier OS curves were detected ( p = 0.76). Survival probabilities were similar between the weighted routine‐care and trial cohorts at 12‐, 24‐, and 36‐ months (0.45 vs. 0.47, 0.31 vs. 0.31, 0.26 vs. 0.23, respectively). Notably, routine care patients had modestly lower survival at 3 months compared to trial participants (0.69 vs. 0.83, respectively).

Conclusion

Our results provide reassurance that cisplatin‐ineligible aUC patients receiving first‐line immunotherapy in routine care experience similar benefits to those observed in trial patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedHumansFemaleMaleAgedRetrospective StudiesMiddle AgedUrologic NeoplasmsAged, 80 and overCarcinoma, Transitional CellCohort StudiesUrinary Bladder NeoplasmsDatabases, Factual

Stichwörter der Autor:innen

bladder cancerepidemiologysurvival analysisurothelial cancer

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Lucy S Wang

Förderung

  • NCI NIH HHS
  • Abramson Cancer Center

Zitieren

APA

Wang, L. S., Hubbard, R. A., & Mamtani, R. (2024). Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5798

Vancouver

Wang LS, Hubbard RA, Mamtani R. Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5798

BibTeX
@article{Wang2024,
  author = {Wang, Lucy S and Hubbard, Rebecca A and Mamtani, Ronac},
  title = {Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5798}
}
Kostenlos starten →